Collectively, the findings of our study offer mechanistic insights into the oncogenic roles of CPNE1 and RACK1 in NSCLC and suggest that dual blockade of MET and EGFR may be a promising clinical therapeutic strategy for NSCLC. The gene discussed is RACK1; the disease is non-small cell lung carcinoma.